Annetta Krebs

3.5k total citations · 2 hit papers
8 papers, 2.8k citations indexed

About

Annetta Krebs is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Radiology, Nuclear Medicine and Imaging. According to data from OpenAlex, Annetta Krebs has authored 8 papers receiving a total of 2.8k indexed citations (citations by other indexed papers that have themselves been cited), including 6 papers in Oncology, 5 papers in Pulmonary and Respiratory Medicine and 2 papers in Radiology, Nuclear Medicine and Imaging. Recurrent topics in Annetta Krebs's work include Lung Cancer Treatments and Mutations (5 papers), Colorectal Cancer Treatments and Studies (3 papers) and Radiomics and Machine Learning in Medical Imaging (2 papers). Annetta Krebs is often cited by papers focused on Lung Cancer Treatments and Mutations (5 papers), Colorectal Cancer Treatments and Studies (3 papers) and Radiomics and Machine Learning in Medical Imaging (2 papers). Annetta Krebs collaborates with scholars based in United States, Germany and Australia. Annetta Krebs's co-authors include Roy S. Herbst, Christian Manegold, Giuseppe Giaccone, David H. Johnson, Judith Ochs, James R. Vasselli, Ronald B. Natale, Abderrahim Fandi, James A. Reeves and Steven D. Averbuch and has published in prestigious journals such as Journal of Clinical Oncology, The Journal of Clinical Endocrinology & Metabolism and The Oncologist.

In The Last Decade

Annetta Krebs

8 papers receiving 2.7k citations

Hit Papers

Gefitinib in Combination With Paclitaxel and Carboplatin ... 2004 2026 2011 2018 2004 2005 400 800 1.2k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2
    2004 1.4k citations Roy S. Herbst, Giuseppe Giaccone et al. Journal of Clinical Oncology profile →
  2. Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials
    2005 518 citations Daphne W. Bell, Thomas J. Lynch et al. Journal of Clinical Oncology profile →

Peers

Annetta Krebs
Toshiyuki Kozuki Japan
Ariel López-Chávez United States
Katherine Liau United States
Haruhiro Yukiue Japan
Viola W. Zhu United States
Carol Peña France
Ryan J. Hartmaier United States
Atsushi Horiike Japan
Michael T. Schweizer United States
Harold Keer United States
Toshiyuki Kozuki Japan
Annetta Krebs
Citations per year, relative to Annetta Krebs Annetta Krebs (= 1×) peers Toshiyuki Kozuki

Countries citing papers authored by Annetta Krebs

Since Specialization
Citations

This map shows the geographic impact of Annetta Krebs's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Annetta Krebs with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Annetta Krebs more than expected).

Fields of papers citing papers by Annetta Krebs

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Annetta Krebs. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Annetta Krebs. The network helps show where Annetta Krebs may publish in the future.

Co-authorship network of co-authors of Annetta Krebs

This figure shows the co-authorship network connecting the top 25 collaborators of Annetta Krebs. A scholar is included among the top collaborators of Annetta Krebs based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Annetta Krebs. Annetta Krebs is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

8 of 8 papers shown
1.
Plimack, Elizabeth R., Patricia LoRusso, Patricia McCoon, et al.. (2013). AZD1480: A Phase I Study of a Novel JAK2 Inhibitor in Solid Tumors. The Oncologist. 18(7). 819–820. 89 indexed citations
2.
Wells, Samuel A., Jessica E. Gosnell, Robert F. Gagel, et al.. (2010). Vandetanib for the Treatment of Patients With Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer. Journal of Clinical Oncology. 28(5). 767–772. 380 indexed citations
3.
Robinson, Bruce G., Luis Paz‐Ares, Annetta Krebs, James R. Vasselli, & Robert I. Haddad. (2010). Vandetanib (100 mg) in Patients with Locally Advanced or Metastatic Hereditary Medullary Thyroid Cancer. The Journal of Clinical Endocrinology & Metabolism. 95(6). 2664–2671. 193 indexed citations
4.
5.
Heymach, John V., Luis Paz‐Ares, Filippo de Braud, et al.. (2008). Randomized Phase II Study of Vandetanib Alone or With Paclitaxel and Carboplatin as First-Line Treatment for Advanced Non–Small-Cell Lung Cancer. Journal of Clinical Oncology. 26(33). 5407–5415. 184 indexed citations
6.
Govindan, Ramaswamy, Ronald B. Natale, James L. Wade, et al.. (2006). Efficacy and safety of gefitinib in chemonaive patients with advanced non-small cell lung cancer treated in an Expanded Access Program. Lung Cancer. 53(3). 331–337. 9 indexed citations
7.
Bell, Daphne W., Thomas J. Lynch, Sara M. Haserlat, et al.. (2005). Epidermal Growth Factor Receptor Mutations and Gene Amplification in Non–Small-Cell Lung Cancer: Molecular Analysis of the IDEAL/INTACT Gefitinib Trials. Journal of Clinical Oncology. 23(31). 8081–8092. 518 indexed citations breakdown →
8.
Herbst, Roy S., Giuseppe Giaccone, Joan H. Schiller, et al.. (2004). Gefitinib in Combination With Paclitaxel and Carboplatin in Advanced Non–Small-Cell Lung Cancer: A Phase III Trial—INTACT 2. Journal of Clinical Oncology. 22(5). 785–794. 1374 indexed citations breakdown →

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Toshiyuki Kozuki Breakdown of academic impact, for papers by Ariel López-Chávez Breakdown of academic impact, for papers by Katherine Liau Breakdown of academic impact, for papers by Haruhiro Yukiue Breakdown of academic impact, for papers by Viola W. Zhu Breakdown of academic impact, for papers by Carol Peña Breakdown of academic impact, for papers by Ryan J. Hartmaier Breakdown of academic impact, for papers by Atsushi Horiike Breakdown of academic impact, for papers by Michael T. Schweizer Breakdown of academic impact, for papers by Harold Keer
Rankless by CCL
2026